Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug;78(2):312-314.
doi: 10.1053/j.ajkd.2020.12.012. Epub 2021 Jan 9.

Effect of Lanthanum Carbonate on Blood Pressure in CKD

Affiliations
Randomized Controlled Trial

Effect of Lanthanum Carbonate on Blood Pressure in CKD

Mitra S Jamshidian et al. Am J Kidney Dis. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure: The authors declare that they have no relevant financial interests.

Peer Review: Received Aug 07, 2020. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, who served as Acting Editor-in-Chief. Accepted in revised form December 5, 2020. The involvement of an Acting Editor-in-Chief was to comply with AJKD’s procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.

Figures

Figure 1.
Figure 1.. Change in BP in Lanthanum vs Non-lanthanum Arms*
a) Change in SBP over the course of the study in lanthanum vs non-lanthanum arms b) Change in DBP over the course of the study in lanthanum vs non-lanthanum arms *Adjusted for age, sex, baseline BP, eGFR, clinical center and baseline number of anti-hypertensives.
Figure 1.
Figure 1.. Change in BP in Lanthanum vs Non-lanthanum Arms*
a) Change in SBP over the course of the study in lanthanum vs non-lanthanum arms b) Change in DBP over the course of the study in lanthanum vs non-lanthanum arms *Adjusted for age, sex, baseline BP, eGFR, clinical center and baseline number of anti-hypertensives.

References

    1. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16(2):520–528. - PubMed
    1. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease [published correction appears in Circulation. 2007 Dec 4;116(23):e556]. Circulation 2005;112(17):2627–2633. - PubMed
    1. Ginsberg C, Houben AJHM, Malhotra R, et al. Serum Phosphate and Microvascular Function in a Population-Based Cohort. Clin J Am Soc Nephrol 2019;14(11):1626–1633. - PMC - PubMed
    1. Mohammad J, Scanni R, Bestmann L, Hulter HN, Krapf R. A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects. J Am Soc Nephrol 2018;29(8):2089–2098. - PMC - PubMed
    1. Ix JH, Isakova T, Larive B, et al. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol 2019;30(6):1096–1108. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources